alnylam
As Associate Director, Multimodal Discovery Platforms at Alnylam, this leadership role oversees the end-to-end delivery and architectural alignment of digital platforms supporting multimodal discovery workflows in Research & Early Development. The position bridges the gap between complex scientific needs and technology solutions, ensuring scalable integration across omics, imaging, and data ecosystems to accelerate target discovery and translational science.
Headquarters
Cambridge, Massachusetts, United States
Company Size
1001-5000 employees
Founded
2002
Alnylam is a biopharmaceutical company that has pioneered RNA interference (RNAi) therapeutics, an innovative class of medicines that treats diseases by silencing the genes that cause or contribute to them. The company develops RNAi-based medicines targeting both rare and prevalent diseases across multiple therapeutic areas, with approved products and a robust investigational pipeline. Driven by science and inspired by patients, Alnylam is committed to delivering transformational medicines that address diseases at their genetic source.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for alnylam.
4% below the average for this role
Scientist II, Computational Biology, AI & Multimodal Target Discovery
PharmaEssentia
Senior Scientist - Computational Discovery & Translational Analytics
lifelancer
Senior Scientist / Principal Scientist, Data Engineer (Multi‑omics)
Digital Biology
Senior Scientist - Computational Discovery & Translational Analytics
lifelancer
Team Leader in Data Science, Disease Area X
Novartis
Scientist or Senior Scientist
UCB